Jump to content

Propentofylline

From Wikipedia, the free encyclopedia
(Redirected from ATC code N06BC02)
Propentofylline
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 3-methyl-1-(5-oxohexyl)-7-propyl-3,7-dihydro-1H-purine-2,6-dione
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.133.568 Edit this at Wikidata
Chemical and physical data
FormulaC15H22N4O3
Molar mass306.366 g·mol−1
3D model (JSmol)
  • CCCn1cnc2c1c(=O)n(c(=O)n2C)CCCCC(=O)C
  • InChI=1S/C15H22N4O3/c1-4-8-18-10-16-13-12(18)14(21)19(15(22)17(13)3)9-6-5-7-11(2)20/h10H,4-9H2,1-3H3
  • Key:RBQOQRRFDPXAGN-UHFFFAOYSA-N
  (verify)

Propentofylline (HWA 285) is a xanthine derivative drug with purported neuroprotective effects.

Pharmacology

[edit]

It is a phosphodiesterase inhibitor,[1] and also acts as an adenosine reuptake inhibitor.[1][2][3]

Uses

[edit]

Propentofylline was studied as a possible treatment for Alzheimer's disease and multi-infarct dementia,[1][4] and has been studied, to a lesser extent, as a possible adjunct in the treatment of ischemic stroke, due to its vasodilating properties.[5][6]

Propentofylline is in use as a veterinary medicine in older dogs.[7]

See also

[edit]
[edit]

References

[edit]
  1. ^ a b c Frampton M, Harvey RJ, Kirchner V (2003). Frampton MA (ed.). "Propentofylline for dementia". The Cochrane Database of Systematic Reviews (2): CD002853. doi:10.1002/14651858.CD002853. PMID 12804440.
  2. ^ Salimi S, Fotouhi A, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Mohammadi MR, et al. (April 2008). "A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32 (3): 726–732. doi:10.1016/j.pnpbp.2007.11.021. PMID 18096287. S2CID 21498202.
  3. ^ Numagami Y, Marro PJ, Mishra OP, Delivoria-Papadopoulos M (June 1998). "Effect of propentofylline on free radical generation during cerebral hypoxia in the newborn piglet". Neuroscience. 84 (4): 1127–1133. doi:10.1016/S0306-4522(97)00542-3. PMID 9578400. S2CID 36155779.
  4. ^ Kittner B, Rössner M, Rother M (September 1997). "Clinical trials in dementia with propentofylline". Annals of the New York Academy of Sciences. 826 (1): 307–316. Bibcode:1997NYASA.826..307K. doi:10.1111/j.1749-6632.1997.tb48481.x. PMID 9329701. S2CID 12493243.
  5. ^ Bath PM, Bath-Hextall FJ (2004). Bath PM (ed.). "Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke". The Cochrane Database of Systematic Reviews (3): CD000162. doi:10.1002/14651858.CD000162.pub2. PMID 15266424.
  6. ^ Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss WD (May 1993). "Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke". Journal of Cerebral Blood Flow and Metabolism. 13 (3): 526–530. doi:10.1038/jcbfm.1993.68. PMID 8478410. S2CID 24909748.
  7. ^ "Launch of tablet to make life easier for dogs in old age". Yorkshire Post. 7 September 2012. Retrieved 28 December 2019.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Propentofylline&oldid=1186018883"